Loading clinical trials...
Loading clinical trials...
Phase I/II Trial of Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Conditions
Interventions
pacritinib
Locations
1
United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Start Date
April 29, 2026
Primary Completion Date
January 1, 2030
Completion Date
January 1, 2035
Last Updated
April 24, 2026
NCT06847867
NCT06465953
NCT05636514
NCT07270978
NCT05292664
NCT06499285
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions